Marine organisms and other novel natural sources of new cancer drugs

Annals of Oncology

Volumn 11, Issue SUPPL. 3, 2000, Pages 235-243

  Schwartsmann, G ^a  

^a UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; 6 HYDROXYMETHYLACYLFULVENE; 6 [4 DEOXY 4 (2,4 TETRADECADIENOYLGLYCYLAMINO) GLYCERO BETA MANNOHEPTOPYRANOSYLAMINO] 9H PURINE; 7 HYDROXYSTAUROSPORINE; ASPARAGINASE MACROGOL; BISANTRENE; BIZELESIN; BRYOSTATIN 1; CAMPTOTHECIN; CYTARABINE; DEHYDRODIDEMNIN B; DEPSIPEPTIDE; DISCODERMOLIDE; DOCETAXEL; DOLASTATIN 10; DOLASTATIN 15; ETOPOSIDE; FLAVOPIRIDOL; FR 901228; GAMMA INTERFERON DERIVATIVE; GEMCITABINE; HALICHONDRIN B; IRINOTECAN; ISOGRANULATIMIDE; MILTEFOSINE; NAVELBINE; NSC 339555; NSC D655649; PACLITAXEL; PHOTOFRIN; PLANT EXTRACT; RACHELMYCIN; RAPAMYCIN; REBECCAMYCIN; RHIZOXIN; SPICAMYCIN; TEMSIROLIMUS; TENIPOSIDE; TOPOTECAN; TRABECTEDIN; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE; ZINOSTATIN;

ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG ISOLATION; DRUG MARKETING; GERM CELL TUMOR; HUMAN; HYPONATREMIA; LEUKEMIA; LYMPHOMA; MARINE ENVIRONMENT; MEDICAL PRACTICE; MYALGIA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PLANT; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0033779370     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/11.suppl_3.235     Document Type: Conference Paper

References (78)

1. Medicinal plants in therapy
2. Natural products in drug discovery and development
3. Discovery and development of antineoplastic agents from natural sources
4. Plant-derived natural products in drug discovery and development: An overview
5. The role of ethnopharmacology in drug development
6. Major microbial diversity initiative recommended
7. Promising new agents under development by the Division of Cancer Treatment, Diagnosis and Centers of the National Cancer Institute
8. The National Cooperative Natural Products Drug Discovery Group (NC-NPDDG) and International Cooperative Biodiversity Group (ICBG) Programs
9. Contributions to the study of marine products: XXXII. The nucleosides of sponges
10. The role of medicinal plants in drug development
11. The ethnobotanical approach to drug discovery: Strengths and limitations
12. Recent progress in the study of anticancer drugs originating from plants and traditional medicines in China
13. Anticancer drugs (Chapter 18)
14. The Vinca alkaloids: A new class of oncolytic agents
15. Combination chemotherapy in the treatment of advanced Hodgkin's disease
16. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide
17. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia
18. Plant anti-tumor agents: I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata
19. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer
20. Irinotecan for colorectal cancer
21. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
22. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer
23. Essential drugs for cancer therapy: A World Health Organization consultation
24. Antitumor activity of 7-ethyl-10-(4-(1-piperidino)-1-piperidino)carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors
25. Adriamycin (NSC 123127) a new antibiotic with antitumor activity
26. Cancer drug discovery and development (Section 1, Chapter 18)
27. Anticancer drugs: Antimetabolite metabolism and natural anticancer agents
28. Clinical highlights from the National Cancer Database: 1996
29. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action
30. Coral reefs, forests, and thermal vents: The worldwide exploration of nature for novel antitumor agents
31. Antitumor marine natural products
32. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel to tubulin polymers, enhances tubuline nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells
33. Synthesis and cytostatic activities of didemnin derivatives
34. A phase II trial of didemnin B in myeloma. A cancer and leukemia group B (CALGB) study
35. Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent
36. Antitumor compounds from tunicates
37. DNA minor groove alkylation by Ecteinascidin 743 indices sequence specific topoisomerase I-mediated DNA damage
38. The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin 10
39. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain
40. Dolastatin-10 induces polyploidy, telomeric associations and apoptosis in a murine melanoma cell line
41. Effect of dolastatin 10 on human non-Hodgkin lymphoma cell lines
42. Novel marine-derived anticancer agent: A phase I clinical, pharmacological and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors
43. Phase I trial of dolastatin-10 in patients with advanced solid tumors
44. The rational design of potential chemotherapeutic agents: Synthesis of bryostatin analogues
45. Modulation of Ciap-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in human early pre-B acute lymphoblastic leukemia cell line REH
46. Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins
47. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: In vitro and in vivo activity
48. Phase I study of bryostatin-1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia
49. Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1
50. A phase I trial of bryostatin 1 in patients with advanced malignancies using a 24 hour intravenous infusion
51. A phase I study of intravenous bryostatin 1 in patients with advanced cancer
52. Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacyfulvene (HMAF, MGI 114)
53. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S
54. A phase I and pharmacokinetic study of the novel mushroom-derived cytotoxin, MGI 114, in patients with advanced cancer
55. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinases (CDK2 and CDK4) in human breast carcinoma cells
56. Phase I clinical and pharmacokinetic trial of flavopiridol
57. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
58. Anticancer drugs: Antimetabolite metabolism and natural anticancer agents
59. Rapamycin and CCI-779
60. Rapamycin inhibition of the GI to S transition is mediated by effects on cyclin D1 mRNA and protein stability
61. CCI-779, a Rapamycin analog and multifaceted inhibitor of signal transduction: A phase I study
62. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968 on Ha-ras transformed NIH3T3 cells
63. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor
64. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. Antitumor activities on experimental tumors in mice
65. Production and biological activity of Rebeccamycin, a novel antitumor agent
66. Phase I clinical and pharmacokinetic study of a rebeccamycin analog (NSC 655649)
67. Immunomodulatory and anti-tumour polysaccharides from medicinal plants
68. Summary of the workshop on drug development, biologic diversity, and economic growth
69. Coral reefs, forests, and thermal vents: The worldwide exploration of nature for novel antitumor agents
70. Amazonian ethnobotany and the search for new drugs
71. High antitumor activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer
72. Ecteinascidin 743: A minor groove alkylator that bends DNA toward the major groove
73. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol
74. The bioprocess-technological potential of the sea
75. Rational design of aromatic polyketide natural products by recombinant assembly of enzymatic units